David R. Walt Receives National Medal of Technology and Innovation
Quanterix (NASDAQ: QTRX) announced that David R. Walt, co-inventor of the Company's Simoa technology, has been awarded the National Medal of Technology and Innovation by the President of the United States. This prestigious award, established by Congress in 1980 and first awarded in 1985, recognizes American innovators who have strengthened the nation's economy and improved quality of life through technological innovation.
The medal, administered by the U.S. Patent and Trademark Office, acknowledges Walt's contributions to technological advancement. According to Masoud Toloue, President and CEO of Quanterix, this recognition highlights the significance of Simoa technology in early disease detection using non-invasive methods. The company has established itself as a leader in Neurology and is expanding into Immunology and Oncology markets.
Quanterix (NASDAQ: QTRX) ha annunciato che David R. Walt, co-inventore della tecnologia Simoa dell'azienda, ha ricevuto la Medaglia Nazionale per la Tecnologia e l'Innovazione dal Presidente degli Stati Uniti. Questo prestigioso riconoscimento, istituito dal Congresso nel 1980 e assegnato per la prima volta nel 1985, celebra gli innovatori americani che hanno rafforzato l'economia nazionale e migliorato la qualità della vita attraverso l'innovazione tecnologica.
La medaglia, amministrata dall'Ufficio Brevetti e Marchi degli Stati Uniti, riconosce i contributi di Walt al progresso tecnologico. Secondo Masoud Toloue, Presidente e CEO di Quanterix, questo riconoscimento sottolinea l'importanza della tecnologia Simoa nella rilevazione precoce delle malattie utilizzando metodi non invasivi. L'azienda si è affermata come leader nella Neurologia ed è in fase di espansione nei mercati dell'Immunologia e dell'Oncologia.
Quanterix (NASDAQ: QTRX) anunció que David R. Walt, co-inventor de la tecnología Simoa de la compañía, ha sido galardonado con la Medalla Nacional de Tecnología e Innovación por el Presidente de los Estados Unidos. Este prestigioso premio, establecido por el Congreso en 1980 y otorgado por primera vez en 1985, reconoce a los innovadores estadounidenses que han fortalecido la economía del país y mejorado la calidad de vida a través de la innovación tecnológica.
La medalla, administrada por la Oficina de Patentes y Marcas de EE. UU., reconoce las contribuciones de Walt al avance tecnológico. Según Masoud Toloue, Presidente y CEO de Quanterix, este reconocimiento resalta la importancia de la tecnología Simoa en la detección temprana de enfermedades mediante métodos no invasivos. La empresa se ha consolidado como líder en Neurología y está expandiéndose en los mercados de Inmunología y Oncología.
Quanterix (NASDAQ: QTRX)는 회사의 Simoa 기술 공동 발명자인 David R. Walt가 미국 대통령으로부터 국가 기술 혁신 메달을 수상했다고 발표했습니다. 이 권위 있는 상은 1980년 의회에 의해 설립되어 1985년에 처음 수여되었으며, 국가의 경제를 강화하고 기술 혁신을 통해 삶의 질을 향상시킨 미국 혁신가들을 인정합니다.
이 메달은 미국 특허청에서 관리하며, Walt의 기술 발전 기여를 인정합니다. Quanterix의 대표이자 CEO인 Masoud Toloue에 따르면, 이 인식은 비침습적인 방법을 사용한 조기 질병 감지에서 Simoa 기술의 중요성을 강조합니다. 이 회사는 신경학 분야에서 선두주자로 자리 잡았으며, 면역학 및 종양학 시장으로도 확장하고 있습니다.
Quanterix (NASDAQ: QTRX) a annoncé que David R. Walt, co-inventeur de la technologie Simoa de l'entreprise, a été récompensé par la Médaille Nationale de la Technologie et de l'Innovation par le Président des États-Unis. Cette prestigieuse distinction, établie par le Congrès en 1980 et décernée pour la première fois en 1985, reconnaît les innovateurs américains qui ont renforcé l'économie nationale et amélioré la qualité de vie grâce à l'innovation technologique.
La médaille, administrée par l'Office des brevets et des marques des États-Unis, reconnaît les contributions de Walt à l'avancement technologique. Selon Masoud Toloue, Président et CEO de Quanterix, cette distinction souligne l'importance de la technologie Simoa dans la détection précoce des maladies par des méthodes non invasives. L'entreprise s'est imposée comme un leader en neurologie et s'étend maintenant aux marchés de l'immunologie et de l'oncologie.
Quanterix (NASDAQ: QTRX) gab bekannt, dass David R. Walt, Mitinhaber der Simoa-Technologie des Unternehmens, von dem Präsidenten der Vereinigten Staaten mit der National Medal of Technology and Innovation ausgezeichnet wurde. Diese angesehene Auszeichnung, die 1980 vom Kongress ins Leben gerufen wurde und 1985 erstmals vergeben wurde, würdigt amerikanische Innovatoren, die die Wirtschaft des Landes gestärkt und die Lebensqualität durch technologische Innovation verbessert haben.
Die Medaille, die vom US-Patent- und Markenamt verwaltet wird, würdigt Walts Beiträge zum technologischen Fortschritt. Laut Masoud Toloue, Präsident und CEO von Quanterix, hebt diese Anerkennung die Bedeutung der Simoa-Technologie bei der frühzeitigen Krankheitsdiagnose mit nicht-invasiven Methoden hervor. Das Unternehmen hat sich als führend in der Neurologie etabliert und erweitert sich in die Bereiche Immunologie und Onkologie.
- Recognition of Simoa technology's importance in early disease detection
- Company's expansion into Immunology and Oncology markets
- Established leadership position in Neurology sector
- None.
Award represents nation’s highest honor for technological achievement
Since it was first awarded in 1985, the National Medal of Technology and Innovation has recognized American innovators whose vision, intellect, creativity, and determination have strengthened America’s economy and improved our quality of life. The medal was established by Congress in 1980 and is administered by the
The Medal is awarded to individuals, teams, companies or divisions of companies for their outstanding contributions to America’s economic, environmental and social well-being. The purpose of the National Medal of Technology and Innovation is to recognize those who have made lasting contributions to America's competitiveness, standard of living, and quality of life through technological innovation, and to recognize those who have made substantial contributions to strengthening the nation's technological workforce.
“We are thrilled that David has received the prestigious honor of the National Medal of Technology and Innovation,” said Masoud Toloue, President and CEO of Quanterix. “This award is not only a testament to David and his lifelong work, but also demonstrates the power of Simoa in detecting disease early, before symptoms appear, using non-invasive methods. Our best-in-class technology has established Quanterix as a leader in Neurology and we are rapidly expanding our presence in other markets such as Immunology and Oncology.”
To learn more about Quanterix, visit www.quanterix.com/company. To learn more about Quanterix’s Simoa® technology, visit www.quanterix.com/simoa-technology.
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,100 peer-reviewed journals. Find additional information about the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106086169/en/
Media Contact:
Marissa Klaassen
media@quanterix.com
Investor Relations Contact:
Joshua Young
ir@quanterix.com
Source: Quanterix Corporation
FAQ
What prestigious award did Quanterix's (QTRX) technology co-inventor receive?
What markets is Quanterix (QTRX) expanding into beyond Neurology?
What is the main application of Quanterix's (QTRX) Simoa technology?
How does this national recognition impact Quanterix's (QTRX) market position?
